Partner Therapeutics Gains FDA Approval for Zenocutuzumab-zbco in NRG1-Fusion Cholangiocarcinoma Five Months Early

An approval delivered more than five months ahead of the FDA goal date signals that the Commissioner's National Priority Review Voucher (CNPV) pilot program can materially compress timelines for rare oncology products, and that manufacturing and supply teams at Partner Therapeutics, Inc. needed to be ready well before the original schedule suggested.

On 8 May 2026, FDA approved zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion, following disease progression on or after prior systemic therapy. The application carried priority review, breakthrough designation, and orphan drug designation, a full stack of expedited program designations under the Guidance for Industry: Expedited Programs for Serious Conditions.

Efficacy data came from the eNRGy trial (NCT02912949), a multicenter, open-label, multi-cohort study. Of 19 efficacy-evaluable patients with NRG1 fusion-positive cholangiocarcinoma, the confirmed overall response rate was 36.8% (95% CI: 16.3, 61.6) by blinded independent central review per RECIST v1.1, with duration of response ranging from 2.8 to 12.9 months. The small evaluable population reflects the rarity of the indication rather than a study design shortfall.

The prescribing information carries warnings and precautions for infusion-related reactions, hypersensitivity and anaphylactic reactions, interstitial lung disease/pneumonitis, left ventricular dysfunction, and embryo-fetal toxicity. The recommended dose is 750 mg as an intravenous infusion every two weeks until disease progression or unacceptable toxicity. QA and pharmacovigilance teams should note that the label's adverse reaction profile, including diarrhea, musculoskeletal pain, fatigue, nausea, and dyspnea, will anchor post-marketing safety surveillance obligations from day one of commercial distribution.

For regulatory affairs leads tracking CNPV pilot outcomes, the five-month acceleration is the more consequential data point. Review timelines that compress this sharply require commercial manufacturing readiness, validated processes, and supply-chain commitments to be in place earlier than conventional PDUFA planning cycles would dictate. Teams relying on standard goal-date buffers for rare oncology submissions should recalibrate their readiness assumptions accordingly.

The degree to which the CNPV pilot sustains this pace across subsequent applications will determine whether accelerated manufacturing readiness becomes a structural requirement for rare-disease sponsors entering the program.

Source: FDA Drugs@FDA / What's New: Drugs RSS Feed, 8 May 2026.